EUVIMEDEUVIMED entdecken
Crossref

Risk-stratified Distant Metastatic Thyroid Cancer with Clinicopathological Factors and BRAF/TERT Promoter Mutations

Xian Cheng, Ying Zhou, Shichen Xu, Huixin Yu, Jing Wu, Jiandong Bao, Li Zhang iD

Experimental and Clinical Endocrinology & Diabetes · 01.11.2023 · 131 (11) · 577-582

DOI: 10.1055/a-2177-1051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.11.2023. Verfasst von Xian Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, C…. Hauptthemen laut MEDLINE: Telomerase, Thyroid Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the prognostic value of clinicopathological factors as well as BRAF and TERT promoter mutations in predicting distant metastasis in patients with papillary thyroid cancer.

Design

The status of BRAF and TERTp mutations were available in 1,208 thyroid cancer patients who received thyroidectomy at Jiangyuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine from January 2008 to December 2021. Based on inclusion criteria, 99 distant metastasis thyroid cancers (DM-TCs) and 1055 patients without DM (Non-DM-TCs) were retrospectively reviewed.

Results

After univariate and multivariate analyses, a risk model was established for DM prediction based on factors: T3/T4 stage, lymph node metastasis (LNM) number over 5, and BRAF/TERT mutations (TLBT). It was defined based on the number of TLBT factors: low risk (no risk factor, n=896), intermediate risk (1 risk factor, n=199), and high risk (≥2 risk factors, n=59). Notably, compared with patients with low and intermediate risks, patients assigned to high TLBT risk have a shorter time of DM disease-free survival. Except for gene mutation, other factors were also included in the 2015 American Thyroid Association (ATA) risk guideline. Comparing with the ATA risk category, this risk model showed a better performance in predicting DM-TCs.

Conclusions

This study proposes a TLBT risk classifier consisting of T3/T4 stages, LNM (n>5), and BRAF+TERTp mutations for predicting DM-TCs. TLBT risk stratification may help clinicians make personalized treatment management and follow-up strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TelomeraseThyroid NeoplasmsHumansProto-Oncogene Proteins B-rafRetrospective StudiesPromoter Regions, GeneticMutation

Substanzen

Proto-Oncogene Proteins B-rafTelomeraseTERT protein, humanBRAF protein, human

Autor:innen und Institutionen

  • NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China.
  • Department of Endocrinology, Jiangyuan Hospital Affiliated to Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China.
  • Department of Radiopharmaceuticals, School of Pharmacy, Nanjing Medical University, Nanjing, China.
  • School of Life Science and Technology, Southeast University, Nanjing, China.

ORCID-Profile: Li Zhang

Zitieren

APA

Cheng, X., Zhou, Y., Xu, S., Yu, H., Wu, J., Bao, J., & Zhang, L. (2023). Risk-stratified Distant Metastatic Thyroid Cancer with Clinicopathological Factors and BRAF/TERT Promoter Mutations. Experimental and Clinical Endocrinology & Diabetes, 131(11), 577-582. https://doi.org/10.1055/a-2177-1051

Vancouver

Cheng X, Zhou Y, Xu S, Yu H, Wu J, Bao J, et al. Risk-stratified Distant Metastatic Thyroid Cancer with Clinicopathological Factors and BRAF/TERT Promoter Mutations. Experimental and Clinical Endocrinology & Diabetes. 2023;131(11):577-582. doi:10.1055/a-2177-1051

BibTeX
@article{Cheng2023,
  author = {Cheng, Xian and Zhou, Ying and Xu, Shichen and Yu, Huixin and Wu, Jing and Bao, Jiandong and Zhang, Li},
  title = {Risk-stratified Distant Metastatic Thyroid Cancer with Clinicopathological Factors and BRAF/TERT Promoter Mutations},
  journal = {Experimental and Clinical Endocrinology & Diabetes},
  year = {2023},
  volume = {131},
  number = {11},
  pages = {577--582},
  doi = {10.1055/a-2177-1051}
}
Kostenlos starten →